Alumis Inc. (ALMS)
ALMS Stock Price Chart
Explore Alumis Inc. interactive price chart. Choose custom timeframes to analyze ALMS price movements and trends.
ALMS Company Profile
Discover essential business fundamentals and corporate details for Alumis Inc. (ALMS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jun 2024
Employees
223.00
Website
https://www.alumis.comCEO
Martin Babler
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Financial Timeline
Browse a chronological timeline of Alumis Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.70, while revenue estimate is $3.62m.
Earnings released on 14 May 2026
EPS came in at -$0.74 surpassing the estimated -$0.74 by +0.37%, while revenue for the quarter reached $1.74m , missing expectations by -15.41%.
Earnings released on 19 Mar 2026
EPS came in at -$0.95 surpassing the estimated -$0.97 by +2.06%, while revenue for the quarter reached $1.93m , missing expectations by -18.36%.
Earnings released on 13 Nov 2025
EPS came in at -$1.06 falling short of the estimated -$0.92 by -15.22%, while revenue for the quarter reached $2.07m , missing expectations by -24.87%.
Earnings released on 13 Aug 2025
EPS came in at -$1.17 falling short of the estimated -$1.11 by -5.41%, while revenue for the quarter reached $2.67m , missing expectations by -15.17%.
Earnings released on 14 May 2025
EPS came in at -$1.82 falling short of the estimated -$1.47 by -23.81%, while revenue for the quarter reached $17.39m , beating expectations by +943.34%.
Earnings released on 19 Mar 2025
EPS came in at -$0.23 surpassing the estimated -$1.40 by +83.57%, while revenue for the quarter reached $1.52m , beating expectations by +51.80%.
Earnings released on 13 Nov 2024
EPS came in at -$1.73 falling short of the estimated -$1.64 by -5.49%.
Earnings released on 13 Aug 2024
EPS came in at -$23.10 falling short of the estimated -$4.50 by -413.33%.
Earnings released on 31 Mar 2024
EPS came in at -$0.96 .
Earnings released on 31 Dec 2023
EPS came in at -$4.50 .
Earnings released on 30 Sept 2023
EPS came in at -$1.13 .
Earnings released on 29 Jun 2023
EPS came in at -$0.70 .
Earnings released on 31 Mar 2023
EPS came in at -$0.69 .
ALMS Stock Performance
Access detailed ALMS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
